Sanofi prostate cancer drug shows 28 pct survival

PARIS, May 27 (BestGrowthStock) – Sanofi-Aventis’ (SASY.PA: )
cabazitaxel candidate prostate cancer drug combined with
prednisone reduced the risk of death by 28 percent compared with
another treatment, the outcome of a final-stage trial showed.

The French drugmaker said on Thursday that the combination
of the treatments led to an improved median overall survival of
15.1 months against 12.7 months in patients who took a
chemotherapy of mitoxantrone with prednisone/prednisolone.

The primary endpoint of the so-called Tropic trial was
overall survival.

Cabazitaxel won priority review from the U.S. Food and Drug
Administration (FDA), meaning the health regulator will take
about six months instead of the usual 10 months to assess if a
drug is efficient and safe to be marketed.

The FDA’s review should happen in the third quarter, Sanofi
said.

Filing for approval in the EU has been completed.

Some 4.9 percent of patients using cabazitaxel died from
side-effects. Sanofi said this was mainly due to neutropenia, a
blood disorder people can get from chemotherapy treatment, and
its complications.

This compared with 1.9 percent using mitoxantrone.

“The development of cabazitaxel is one of many
investigational compounds we hope to present to the cancer
community in the months and years to come,” Debasish
Roychowdhury, Sanofi’s oncology senior vice president, said.

The clinical trial results will be presented at the 2010
American Society of Clinical Oncology (ASCO) on June 6.

Stock Market Report

(Reporting by Caroline Jacobs; Editing by David Cowell)

Sanofi prostate cancer drug shows 28 pct survival